About LinusBio
Our mission
Bringing precision exposome medicine for complex conditions lacking biomarkers with evidence of important clinical utility.
Originating from the world’s leading exposome laboratory at Mount Sinai Health System, LinusBio has developed a technology platform that builds on breakthroughs in exposome sequencing by researcher, founder, and CEO Dr. Manish Arora.
The Company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease, oncology and more.
"Our mission is simple: to deliver better outcomes for people and families affected by complex health conditions. We chose to focus on autism first for many considerations, an important one of them is the dramatically different trajectory in cases of an early detection and effective intervention. The impact on the patient and the patient’s family can be substantial. We’re proud to launch the LinusBio platform to meet the tremendous need for better, faster, and comprehensive diagnostics and treatments for a range of conditions and diseases.”
Roadmap
Milestones and achievements
A pivotal year of growth
The world’s first Institute for Exposomic Research established at Mount Sinai in 2013 with Manish Arora, PhD as the co-founder and director of environmental exposure and precision environmental medicine laboratories, leading a team of over 50 scientists advancing research in a vast array of diseases that are national health priorities, including autism, ALS, cancers, and gastrointestinal disorders.
Team
Meet the minds driving innovation at LinusBio
Our leadership team combines expertise, vision, and dedication to push the boundaries of biomedics. Learn more about the individuals shaping LinusBio's mission to transform healthcare through groundbreaking research and development.
LinusBio
Board members
